Neural Biomarkers of Electroconvulsive Therapy Response

Description

In the proposed study, the investigators will utilize resting-state functional MRI (fMRI) and structural MRI-based electrical field modeling to study the effect of electroconvulsive therapy on human neural circuitry. Our study will recruit patients who are beginning treatment with bilateral electroconvulsive therapy (N=75). Our design will be longitudinal where patients will be followed up until their 8th week electroconvulsive therapy clinically. The primary measure of interest will be the slope of clinical change estimated with mixed effect modeling (see Approach). Secondary measures will be the cognitive performance change between baseline and the 8th week electroconvulsive therapy time point.

Conditions

Electroconvulsive Therapy Treated Patients

Talk to us

Study Overview

On this page

Study Details

Study overview

In the proposed study, the investigators will utilize resting-state functional MRI (fMRI) and structural MRI-based electrical field modeling to study the effect of electroconvulsive therapy on human neural circuitry. Our study will recruit patients who are beginning treatment with bilateral electroconvulsive therapy (N=75). Our design will be longitudinal where patients will be followed up until their 8th week electroconvulsive therapy clinically. The primary measure of interest will be the slope of clinical change estimated with mixed effect modeling (see Approach). Secondary measures will be the cognitive performance change between baseline and the 8th week electroconvulsive therapy time point.

Neural Biomarkers of Electroconvulsive Therapy Response in Schizophrenia

Neural Biomarkers of Electroconvulsive Therapy Response

Condition
Electroconvulsive Therapy Treated Patients
Intervention / Treatment

-

Contacts and Locations

Glen Oaks

The Zucker Hillside Hospital, Glen Oaks, New York, United States, 11004

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. current positive symptoms rated ≥4 (moderate) on one or more of these BPRS 53 items: hallucinatory behavior, unusual thought content, suspiciousness, conceptual disorganization;
  • 2. has failed at least one trial of treatment with antipsychotic drug, lasting 6 weeks in duration,
  • 3. competent and willing to sign informed consent;
  • 4. for women, negative pregnancy test and agreement to use a medically accepted birth control method; and
  • 5. Diagnostic and Statistical Manual (DSM)-IV diagnosis of schizophrenia, schizoaffective or schizophreniform disorder.
  • 1. serious neurological or endocrine disorder;
  • 2. any medical condition which requires treatment with a medication with psychotropic effects;
  • 3. significant risk of suicidal or homicidal behavior;
  • 4. cognitive (MMSE ≤ 23) or language limitations that would preclude subjects providing informed consent;
  • 5. contraindications to treatment with electroconvulsive therapy;
  • 6. contraindications to magnetic resonance imaging (e.g. pacemaker)

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Northwell Health,

Miklos Argyelan, MD, PRINCIPAL_INVESTIGATOR, The Zucker Hillside Hospital

Study Record Dates

2025-07-01